PepJunkie Home of the Peptonauts
More
HomeThe PulseAtlasDiscussHunter-GathererResearchProfileSearch

Research

Cetrorelix — living evidence map

The Atlas page holds the claims; this is how its evidence evolved.

Summary

Cetrorelix is a decapeptide GnRH (LHRH) antagonist: unlike agonists it suppresses LH and FSH at once, without an initial surge, by competitive receptor blockade; after phase III trials in IVF it became the first LHRH antagonist approved for clinical use. · pmid:10972520

In 65 women undergoing ovarian stimulation for IVF, a single 3 mg or 2 mg injection of cetrorelix prevented LH surges for at least three days. · pmid:9806259

Identity

PubChem CID 25074887: Cetrorelix, C70H92ClN17O14, 1431.0 g/mol. · pubchem:25074887

CAS registry number 120287-85-6, 130143-01-0. · pubchem:25074887

Where the evidence actually sits

Established50%
Emerging50%

Proportion of the 2 claims about Cetrorelix standing at each tier. Community volume is shown on the Consensus tab beside this and is never averaged into it.

Living evidence history

The use of a GnRH antagonist (Cetrorelix) in a single dose protocol in IVF-embryo transfer: a dose finding study of 3 versus 2 mg. (1998) · emergingThe LHRH antagonist cetrorelix: a review. (2000) · established19982000

2 resolved citations, oldest to newest, coloured by tier. Retractions and contradictions land here as they are recorded.

Structure

No structure representation on record. PepJunkie draws only what an authoritative record supplies; for a peptide that is the residue sequence, and none has been curated for Cetrorelix yet.

Dose evidence, rung by rung

A studied human dose exists on file. Open the rung: the dose is the paper's, in its context, never PepJunkie's.

  1. Approved-label dose · a resolved regulatory document names a labelled dose

    nothing resolved on this rung

  2. Studied human doses · resolved human studies at the established tier
    • The LHRH antagonist cetrorelix: a review. · pmid 10972520 · 2000
  3. Observational evidence · resolved human data at the emerging tier: thin, or contested
    • The use of a GnRH antagonist (Cetrorelix) in a single dose protocol in IVF-embryo transfer: a dose finding study of 3 versus 2 mg. · pmid 9806259 · 1998
  4. Community-reported protocols · protocol propositions from distinct members, counted once per human

    nothing resolved on this rung

  5. Preclinical evidence · resolved animal, cell or mechanistic work

    nothing resolved on this rung

2 resolved citations, 0 unresolved (an unresolved citation lends nothing). Community volume is its own rung and is never averaged into the evidence rungs.